Real-time Estimate
Cboe BZX
20:04:07 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
18.32
USD
|
+2.46%
|
|
+7.17%
|
+4.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
607
|
1,203
|
810.8
|
1,042
|
1,234
|
1,268
|
-
|
-
|
Enterprise Value (EV)
1 |
560.1
|
1,096
|
694.4
|
924.8
|
1,126
|
1,026
|
882.3
|
961
|
P/E ratio
|
-3.7
x
|
-6.77
x
|
-5.12
x
|
5.76
x
|
87.7
x
|
-122
x
|
32.7
x
|
29.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
21
x
|
4.73
x
|
4.57
x
|
3.28
x
|
2.41
x
|
1.95
x
|
EV / Revenue
|
-
|
-
|
18
x
|
4.2
x
|
4.17
x
|
2.65
x
|
1.68
x
|
1.48
x
|
EV / EBITDA
|
-3.34
x
|
-7.07
x
|
-4.5
x
|
76
x
|
-49.3
x
|
-48.5
x
|
9.59
x
|
16.9
x
|
EV / FCF
|
-3.47
x
|
-8.01
x
|
-5.48
x
|
162
x
|
85.5
x
|
54
x
|
42
x
|
11.2
x
|
FCF Yield
|
-28.8%
|
-12.5%
|
-18.2%
|
0.62%
|
1.17%
|
1.85%
|
2.38%
|
8.95%
|
Price to Book
|
2.7
x
|
3.86
x
|
4.39
x
|
2.64
x
|
2.87
x
|
1.81
x
|
1.8
x
|
-
|
Nbr of stocks (in thousands)
|
54,881
|
68,075
|
68,888
|
69,532
|
70,338
|
70,940
|
-
|
-
|
Reference price
2 |
11.06
|
17.67
|
11.77
|
14.98
|
17.54
|
17.88
|
17.88
|
17.88
|
Announcement Date
|
26/02/20
|
23/02/21
|
22/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
38.54
|
220.2
|
270.3
|
386.8
|
525.4
|
651
|
EBITDA
1 |
-167.9
|
-155
|
-154.3
|
12.18
|
-22.86
|
-21.15
|
91.99
|
57
|
EBIT
1 |
-170
|
-157.4
|
-156.6
|
9.773
|
-25.2
|
-10.46
|
31.69
|
53.2
|
Operating Margin
|
-
|
-
|
-406.38%
|
4.44%
|
-9.32%
|
-2.7%
|
6.03%
|
8.17%
|
Earnings before Tax (EBT)
1 |
-163.9
|
-156.2
|
-156.5
|
11.03
|
-16.65
|
-5.816
|
43.36
|
70.13
|
Net income
1 |
-161.9
|
-161.4
|
-157.9
|
183.4
|
14.08
|
-10.79
|
38.76
|
46.63
|
Net margin
|
-
|
-
|
-409.72%
|
83.28%
|
5.21%
|
-2.79%
|
7.38%
|
7.16%
|
EPS
2 |
-2.990
|
-2.610
|
-2.300
|
2.600
|
0.2000
|
-0.1461
|
0.5467
|
0.6150
|
Free Cash Flow
1 |
-161.6
|
-136.8
|
-126.7
|
5.702
|
13.17
|
19
|
21
|
86
|
FCF margin
|
-
|
-
|
-328.75%
|
2.59%
|
4.87%
|
4.91%
|
4%
|
13.21%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
46.83%
|
-
|
-
|
22.83%
|
150.87%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
3.11%
|
93.52%
|
-
|
54.18%
|
184.41%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/02/20
|
23/02/21
|
22/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
18.74
|
32.19
|
26.97
|
99.14
|
61.88
|
48.34
|
71.47
|
67.05
|
83.4
|
79.86
|
91.78
|
101.2
|
109.5
|
128.3
|
119.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.621
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.13
|
-23.32
|
-19.37
|
46.41
|
6.047
|
-11.2
|
-3.154
|
-10.93
|
0.081
|
-16.54
|
-5.298
|
-0.9637
|
-4.803
|
16.12
|
-
|
Operating Margin
|
-192.75%
|
-72.44%
|
-71.81%
|
46.82%
|
9.77%
|
-23.16%
|
-4.41%
|
-16.3%
|
0.1%
|
-20.71%
|
-5.77%
|
-0.95%
|
-4.39%
|
12.57%
|
-
|
Earnings before Tax (EBT)
1 |
-36.05
|
-23.28
|
-19.26
|
46.74
|
6.841
|
-9.364
|
-1.239
|
-8.499
|
2.45
|
-14.28
|
-4.489
|
-1.379
|
1.014
|
-
|
-
|
Net income
1 |
-36.33
|
-25.21
|
-19.98
|
224.1
|
4.461
|
-12.27
|
14.97
|
-14.12
|
25.24
|
-17.7
|
-4.489
|
-1.379
|
0.971
|
-
|
-
|
Net margin
|
-193.83%
|
-78.32%
|
-74.08%
|
226.05%
|
7.21%
|
-25.38%
|
20.95%
|
-21.07%
|
30.26%
|
-22.17%
|
-4.89%
|
-1.36%
|
0.89%
|
-
|
-
|
EPS
2 |
-0.5300
|
-0.3600
|
-0.2900
|
3.180
|
0.0600
|
-0.1800
|
0.2100
|
-0.2000
|
0.3500
|
-0.2500
|
-0.0750
|
-0.0350
|
-0.0300
|
0.0950
|
0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/22
|
03/05/22
|
03/08/22
|
01/11/22
|
28/02/23
|
02/05/23
|
25/07/23
|
31/10/23
|
28/02/24
|
23/04/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
46.9
|
107
|
116
|
117
|
108
|
242
|
386
|
307
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-162
|
-137
|
-127
|
5.7
|
13.2
|
19
|
21
|
86
|
ROE (net income / shareholders' equity)
|
-64.1%
|
-60.1%
|
-63.6%
|
63.1%
|
3.37%
|
6.38%
|
-2.49%
|
-
|
ROA (Net income/ Total Assets)
|
-56.2%
|
-53.4%
|
-54.2%
|
53%
|
2.86%
|
-2.82%
|
-2.19%
|
-
|
Assets
1 |
288.2
|
302
|
291.1
|
346.2
|
493
|
382.3
|
-1,767
|
-
|
Book Value Per Share
2 |
4.100
|
4.570
|
2.680
|
5.680
|
6.100
|
9.860
|
9.960
|
-
|
Cash Flow per Share
2 |
-
|
-2.210
|
-1.840
|
0.0800
|
0.1800
|
0.7600
|
1.460
|
-
|
Capex
1 |
3.2
|
0.28
|
0.42
|
0.11
|
0.13
|
5
|
5
|
-
|
Capex / Sales
|
-
|
-
|
1.08%
|
0.05%
|
0.05%
|
1.29%
|
0.95%
|
-
|
Announcement Date
|
26/02/20
|
23/02/21
|
22/02/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
17.88
USD Average target price
29.2
USD Spread / Average Target +63.31% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.45% | 1.27B | | -2.64% | 103B | | +1.42% | 95.28B | | +1.46% | 22.15B | | -15.76% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -12.82% | 16.05B | | +5.09% | 13.68B | | +33.90% | 12.17B |
Bio Therapeutic Drugs
|